Filter Results:
(563)
Show Results For
- All HBS Web
(563)
- People (4)
- News (151)
- Research (350)
- Events (2)
- Multimedia (4)
- Faculty Publications (172)
Show Results For
- All HBS Web
(563)
- People (4)
- News (151)
- Research (350)
- Events (2)
- Multimedia (4)
- Faculty Publications (172)
- January 2024
- Article
Cost of Exempting Sole Orphan Drugs from Medicare Negotiation
By: Matthew Vogel, Olivia Zhao, William B. Feldman, Amitabh Chandra, Aaron S. Kesselheim and Benjamin N. Rome
Importance: The Inflation Reduction Act (IRA) requires Medicare to negotiate prices for some high-spending drugs but exempts drugs approved solely for the treatment of a single rare disease.
Objective: To estimate Medicare spending and global... View Details
Objective: To estimate Medicare spending and global... View Details
Vogel, Matthew, Olivia Zhao, William B. Feldman, Amitabh Chandra, Aaron S. Kesselheim, and Benjamin N. Rome. "Cost of Exempting Sole Orphan Drugs from Medicare Negotiation." JAMA Internal Medicine 184, no. 1 (January 2024): 63–69.
- 2022
- Working Paper
Exploring the Relationship between Team Diversity, Psychological Safety and Team Performance: Evidence from Pharmaceutical Drug Development
By: Henrik Bresman and Amy C. Edmondson
Breakthrough performance in teams requires pooling diverse perspectives and expertise. To realize the potential of diversity, communicating and translating across differences is essential. However, left to their own devices, diverse teams tend to underperform, in part... View Details
Keywords: Teams; Psychological Safety; Groups and Teams; Diversity; Interpersonal Communication; Performance
Bresman, Henrik, and Amy C. Edmondson. "Exploring the Relationship between Team Diversity, Psychological Safety and Team Performance: Evidence from Pharmaceutical Drug Development." Harvard Business School Working Paper, No. 22-055, February 2022.
- October 1987 (Revised November 1994)
- Case
Boston Fights Drugs (A): Designing Communications Research
Describes in detail the research mounted by five individuals with a $20,000 budget to combat drug abuse among Boston's school-going population. Using the focus group methodology they discover that most of the current anti-drug advertising is useless. They create their... View Details
Keywords: Budgets and Budgeting; Misleading and Fraudulent Advertising; Communication Intention and Meaning; Brands and Branding; Performance Evaluation; Research and Development; Segmentation; Pharmaceutical Industry; Boston
Rangan, V. Kasturi. "Boston Fights Drugs (A): Designing Communications Research." Harvard Business School Case 588-031, October 1987. (Revised November 1994.)
- 1999
- Chapter
The Economics of Drug Discovery
By: Rebecca M. Henderson and Iain Cockburn
Henderson, Rebecca M., and Iain Cockburn. "The Economics of Drug Discovery." Chap. 5 in Pharmaceutical Innovation, edited by Ralph Landau, Basil Achilladelis, and Alexander Scriabine, 308–331. Philadelphia: Chemical Heritage Press, 1999.
- December 2020 (Revised May 2021)
- Background Note
Tales of Life-changing Innovations: Living Drugs | Note on the Development of CAR-T Therapies (through 2019)
By: Amar Bhidé and Srikant M. Datar
Bhidé, Amar, and Srikant M. Datar. "Tales of Life-changing Innovations: Living Drugs | Note on the Development of CAR-T Therapies (through 2019)." Harvard Business School Background Note 321-063, December 2020. (Revised May 2021.)
- March 2010 (Revised May 2012)
- Case
Myelin Repair Foundation: Accelerating Drug Discovery Through Collaboration
By: Karim R. Lakhani and Paul R. Carlile
This case presents the Myelin Repair Foundation's accelerated research collaboration model for drug discovery. It highlights the challenges of building a multi-disciplinary and multi-institutional research collaboration that is attempting to create a treatment for... View Details
Keywords: Research and Development; Intellectual Property; Risk and Uncertainty; Strategic Planning; Collaborative Innovation and Invention; Health Disorders; Pharmaceutical Industry; Biotechnology Industry; Health Industry
Lakhani, Karim R., and Paul R. Carlile. "Myelin Repair Foundation: Accelerating Drug Discovery Through Collaboration." Harvard Business School Case 610-074, March 2010. (Revised May 2012.)
- May 2005
- Supplement
GlaxoSmithKline: Reorganizing Drug Discovery (B)
By: Robert S. Huckman and Eli Strick
Supplements the (A) case. View Details
Keywords: Mergers and Acquisitions; Decisions; Operations; Performance; Research and Development; Restructuring; Organizations; Pharmaceutical Industry
Huckman, Robert S., and Eli Strick. "GlaxoSmithKline: Reorganizing Drug Discovery (B)." Harvard Business School Supplement 605-075, May 2005.
- September 2014
- Case
Pfizer's Centers for Therapeutic Innovation (CTI)
By: Gary Pisano, James Weber and Kait Szydlowski
In 2010, Pfizer established four small research units in New York, Boston, San Francisco, and San Diego located close to several premier Academic Medical Centers (AMCs), or hospitals with adjoining medical schools. The goal of these units was to redesign collaboration... View Details
Keywords: Drug Development; Academic Collaboration; Research And Development; Innovation; Translational Research; Management; Operations; Problems and Challenges; Research; Science; Information Technology; Strategy; Biotechnology Industry; Pharmaceutical Industry; North and Central America; Europe; Asia
Pisano, Gary, James Weber, and Kait Szydlowski. "Pfizer's Centers for Therapeutic Innovation (CTI)." Harvard Business School Case 615-024, September 2014.
- July 2010
- Case
Metabical: Positioning and Communications Strategy for a New Weight Loss Drug
By: John A. Quelch and Heather Beckham
Cambridge Sciences Pharmaceuticals (CSP) expects final approval for its revolutionary weight loss drug, Metabical. Metabical will be the only weight loss drug with FDA approval that is also clinically proven to be effective for moderately overweight people. Barbara... View Details
Keywords: Product Positioning; Marketing Communications; Product Launch; Consumer Behavior; Pharmaceutical Industry; United States
Quelch, John A., and Heather Beckham. "Metabical: Positioning and Communications Strategy for a New Weight Loss Drug." Harvard Business School Brief Case 104-240, July 2010.
- January 2023
- Case
Cleave Therapeutics: Taking a Risk on Oncology Drug Discovery
By: Regina Herzlinger and Brian Walker
What should a successful executive (HBS Baker Scholar) assess as her next move as the CEO of a firm with a promising and yet uncertain new drug? Amy Burroughs’ mandate to successfully commercialize Cleave Therapeutics’ drug for a cancer with no current successful... View Details
Keywords: Product Development; Leadership; Health Testing and Trials; Research and Development; Risk and Uncertainty; Financial Condition; Partners and Partnerships; Pharmaceutical Industry
Herzlinger, Regina, and Brian Walker. "Cleave Therapeutics: Taking a Risk on Oncology Drug Discovery." Harvard Business School Case 323-045, January 2023.
- 01 Mar 2011
- News
Fixing What Ails the Drug Industry
echoed Hamburg’s call for improvements in regulation, but he also emphasized the innovation side of the balancing act between safety and product development. “Reinvent invention,” he told the audience. The industry must get smarter about View Details
- January 2018
- Teaching Note
BeiGene
By: Willy Shih and Jimmy Zhang
Teaching Note for HBS No. 618-033. View Details
- Article
Assessing the Food and Drug Administration's Risk-Based Framework for Software Precertification with Top Health Apps in the United States: Quality Improvement Study
By: Noy Alon, Ariel Dora Stern and John Torous
BACKGROUND: As the development of mobile health apps continues to accelerate, the need to implement a framework that can standardize categorizing these apps to allow for efficient, yet robust regulation grows. However, regulators and researchers are faced with numerous... View Details
Keywords: Mobile Health; Smartphone; Food And Drug Administration; Risk-based Framework; Health Care and Treatment; Mobile and Wireless Technology; Applications and Software; Framework
Alon, Noy, Ariel Dora Stern, and John Torous. "Assessing the Food and Drug Administration's Risk-Based Framework for Software Precertification with Top Health Apps in the United States: Quality Improvement Study." JMIR mHealth and uHealth 8, no. 10 (October 2020).
- November 2006 (Revised July 2008)
- Case
Eli Lilly: Developing Cymbalta
By: Elie Ofek and Ron Laufer
Anticipating the expiration of its Prozac patent, Eli Lilly has to make tough decisions regarding the development of its next-generation antidepressant drug. In particular, the company needs to decide whether to first establish that once-a-day dosing for Cymbalta... View Details
Keywords: Decision Choices and Conditions; Marketing Strategy; Product Launch; Product Development; Research and Development; Pharmaceutical Industry
Ofek, Elie, and Ron Laufer. "Eli Lilly: Developing Cymbalta." Harvard Business School Case 507-044, November 2006. (Revised July 2008.)
- November 2009 (Revised March 2010)
- Case
Managing Drugs on the Forefront of Personalized Medicine: The Erbitux and Vectibix Story
By: Richard G. Hamermesh, Raju Kucherlapati and Rachel Gordon
In May 2007, Amgen Inc. (Amgen) received disappointing news from the European Medicines Agency (EMEA) that its drug Vectibix, developed to fight metastatic colorectal cancer, had been rejected. This was especially surprising news given that a similar rival drug had... View Details
Keywords: Entrepreneurship; Governing Rules, Regulations, and Reforms; Health Testing and Trials; Marketing Strategy; Product Positioning; Genetics; Biotechnology Industry; Europe; United States
Hamermesh, Richard G., Raju Kucherlapati, and Rachel Gordon. "Managing Drugs on the Forefront of Personalized Medicine: The Erbitux and Vectibix Story." Harvard Business School Case 810-066, November 2009. (Revised March 2010.)
- 12 Jun 2018
- Research & Ideas
In a Landscape of 'Me Too' Drug Development, What Spurs Radical Innovation?
their cash reserves have suddenly expanded—they tend to put that extra budget towards more exploratory projects,” says Harvard Business School Assistant Professor Joshua Krieger. He co-authored the study Developing Novel View Details
- November 2018
- Case
David Hysong and SHEPHERD Therapeutics
By: Ananth Raman, John Masko and Aldo Sesia
In 2016, David Hysong, at age 27, found out he had a rare, incurable cancer. Rather than wait around to die, Hysong, a recent graduate of Harvard Divinity School, decided to launch a biotechnology company called Shepherd Therapeutics to development treatments for his... View Details
- July – August 2000
- Article
Drug Industry Mergers Won't Necessarily Benefit R&D
Henderson, Rebecca M. "Drug Industry Mergers Won't Necessarily Benefit R&D." Research-Technology Management 43, no. 4 (July–August 2000): 10–11.
- September 2022
- Article
Find and Replace: R&D Investment Following the Erosion of Existing Products
By: Joshua L. Krieger, Xuelin Li and Richard T. Thakor
How do innovative firms react when existing products experience negative shocks? We explore this question with detailed project-level data from drug development firms. Using FDA Public Health Advisories as idiosyncratic negative shocks to approved drugs, we first... View Details
Keywords: R＆D Investments; Drug Development; Product Shocks; M＆A; Biopharmaceutical Industry; FDA; System Shocks; Research and Development; Investment; Decision Making; Pharmaceutical Industry
Krieger, Joshua L., Xuelin Li, and Richard T. Thakor. "Find and Replace: R&D Investment Following the Erosion of Existing Products." Management Science 68, no. 9 (September 2022): 6552–6571.
- 2024
- Working Paper
Dusting Off the Old Ones: Drug Licensing to Startups, Innovation Success and Efficiency
By: Mosab Hammoudeh, Joshua Lev Krieger and Jiajie Xu
This paper investigates whether moving R&D from incumbents to startups can increase innovation. Using comprehensive drug development data, we examine the outcomes of drug projects licensed from large firms to startups. We find that these projects licensed to startups... View Details
Keywords: Product Development; Innovation and Invention; Business Startups; Research and Development; Performance Efficiency; Pharmaceutical Industry
Hammoudeh, Mosab, Joshua Lev Krieger, and Jiajie Xu. "Dusting Off the Old Ones: Drug Licensing to Startups, Innovation Success and Efficiency." Harvard Business School Working Paper, No. 24-067, March 2024.